Regorafenib May Improve PFS for Patients With Metastatic Sarcoma

Share this content:
Regorafenib provides a statistically significant benefit for non-liposarcoma patients with pre-treated, metastatic sarcoma.
Regorafenib provides a statistically significant benefit for non-liposarcoma patients with pre-treated, metastatic sarcoma.

Regorafenib may provide clinical benefit to patients with 1 of several types of sarcoma, according to a study presented at the 2016 American Society of Clinical Oncology (ASCO) meeting.1

In this double-blind, randomized, placebo-controlled phase 2 study, researchers enrolled 181 patients with metastatic sarcoma who had received at least 3 prior treatments. Sarcomas were grouped by type, which included liposarcoma, leiomyosarcoma, synovial sarcoma, and other types of soft-tissue sarcoma.

Eighty-nine patients were randomized to receive regorafenib; 92 were given a placebo. Only 4 partial responses were observed in the non-placebo cohort: 1 patient with synovial sarcoma, and 3 with “other types.” Aside from liposarcoma patients, those who received regorafenib had an average progression-free survival of 3.0 more months (hazard ratio, .36; P < .0001) than those who received a placebo; average overall survival was 4.4 more months (hazard ratio, .67; P = .06) in the non-placebo cohort.

RELATED: Adding Olaratumab to Doxorubicin Improves Survival in Soft-tissue Sarcoma

Despite these results, the researchers concluded that regorafenib provides a statistically significant benefit for non-liposarcoma patients with pre-treated, metastatic sarcoma. Common adverse events in the non-placebo cohort included asthenia, diarrhea, mucositis, Hand-Foot syndrome, anorexia, and arterial hypertension.

Reference

1. Penel N, Mir O, Italiano A, Blay JY, Wallet J, Bertucci F, et al. Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial. J Clin Oncol. 2016; 34 (suppl; abstr 11003).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters